EA202091391A3 - CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1,5-ANHYDRO-1-C- (3 - ((Phenyl) METHYL) PHENYL) -D-GLUCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES - Google Patents

CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1,5-ANHYDRO-1-C- (3 - ((Phenyl) METHYL) PHENYL) -D-GLUCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Info

Publication number
EA202091391A3
EA202091391A3 EA202091391A EA202091391A EA202091391A3 EA 202091391 A3 EA202091391 A3 EA 202091391A3 EA 202091391 A EA202091391 A EA 202091391A EA 202091391 A EA202091391 A EA 202091391A EA 202091391 A3 EA202091391 A3 EA 202091391A3
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
diabetes
glucitol
anhydro
complexes
Prior art date
Application number
EA202091391A
Other languages
Russian (ru)
Other versions
EA202091391A2 (en
Inventor
Джек З. Гугутас
Хильдегард Лобингер
Шривидья Рамакришнан
Прашант П. Дешпанде
Джеффри Т. Бйн
Чиаджень Лай
Ченьчи Ванг
Петер Рибель
Джон Энтони Гроссо
Александра А. Нёршль
Джанак Сингх
Джон Д. Димарко
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/765,481 external-priority patent/US7919598B2/en
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202091391A2 publication Critical patent/EA202091391A2/en
Publication of EA202091391A3 publication Critical patent/EA202091391A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к кристаллическим формам соединения формулы Iгде R1, R2, R2a, R3 и R4 являются такими, как определено в настоящей заявке, в частности к фармацевтическим композициям, содержащим кристаллические формы, к способам их получения, а также к способам лечения заболеваний, таких как диабет, с использованием указанных кристаллических форм.The present invention relates to crystalline forms of a compound of formula I, wherein R1, R2, R2a, R3 and R4 are as defined in this application, in particular to pharmaceutical compositions containing crystalline forms, to methods for their preparation, as well as to methods of treating diseases such like diabetes, using the indicated crystal forms.

EA202091391A 2007-06-20 2007-06-21 CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1,5-ANHYDRO-1-C- (3 - ((Phenyl) METHYL) PHENYL) -D-GLUCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES EA202091391A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/765,481 US7919598B2 (en) 2006-06-28 2007-06-20 Crystal structures of SGLT2 inhibitors and processes for preparing same

Publications (2)

Publication Number Publication Date
EA202091391A2 EA202091391A2 (en) 2020-10-30
EA202091391A3 true EA202091391A3 (en) 2020-12-30

Family

ID=73129309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091391A EA202091391A3 (en) 2007-06-20 2007-06-21 CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1,5-ANHYDRO-1-C- (3 - ((Phenyl) METHYL) PHENYL) -D-GLUCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Country Status (1)

Country Link
EA (1) EA202091391A3 (en)

Also Published As

Publication number Publication date
EA202091391A2 (en) 2020-10-30

Similar Documents

Publication Publication Date Title
EA200900066A1 (en) CRYSTAL SOLVATES AND COMPLEXES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLYCITOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT
MA32175B1 (en) Oxadiazoanthracenes for the treatment of diabetes
EA201001595A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
ATE442349T1 (en) DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
CY1116885T1 (en) Substituted cyclohexylmethyl derivatives
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
EA201001682A1 (en) Derivatives of phenyl and benzodioxynyl-substituted indazols
EA200901138A1 (en) DERIVATIVES OF DIANILINOPYRIMIDINE AS KEEIN INHIBITORS WEE1, PHARMACEUTICAL COMPOSITION AND USE
MX2009008439A (en) Novel inhibitors hepatitis c virus replication.
EA200901133A1 (en) DERIVATIVES OF DIANILINOPYRIMIDINE AS KEEIN INHIBITORS WEE1, PHARMACEUTICAL COMPOSITION AND USE
CY1108445T1 (en) NEW METHOD OF COMPOSITION AND NEW CRYSTAL FORM OF ANGOMELATIN AS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA200700096A1 (en) DERIVATIVES 2-CARBAMID-4-PHENYL THIAZOLE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION IN THERAPY
EA200901573A1 (en) Heteroaryl Thiazole Substituents
NO20091626L (en) MGluR5 modulators
EA201070442A1 (en) NEW sEH INHIBITORS AND THEIR APPLICATION
PE20091425A1 (en) AMINOTIAZOLE DERIVATIVES
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
EA201071019A1 (en) CRYSTAL FORMS OF DERIVATIVES OF PHENYLAMINOPYRIMIDINE
DE602008001725D1 (en) 1- (1-BENZYLPIPERIDIN-4-YL) BENZIMIDAZOLE-5-CARBOXYLENE DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS
DK1723138T3 (en) Substituted benzimidazoles and their use to induce apoptosis
EA201170722A1 (en) LACTAMS AS BETA SECRETASE INHIBITORS
ATE543803T1 (en) 3-Ä2-(3-AZYLAMINO-2-OXO-2H-PYRIDINE-1-YL)ACETYLAMINOÜ-4-OXOPENTANIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS
NO20085317L (en) Imidazoazepinonforbindelser
DE602004008959D1 (en) BENZOÄBÜÄ1,4ÜDIOXEPINDERIVATE
EA200900732A1 (en) CRYSTALLINE POTASSIUM SALT OF ANALOGUES LIPOXIN A